These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 36872947)

  • 1. Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.
    Veneziani AC; Scott C; Wakefield MJ; Tinker AV; Lheureux S
    Ther Adv Med Oncol; 2023; 15():17588359231157644. PubMed ID: 36872947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP Inhibitors Resistance: Mechanisms and Perspectives.
    Giudice E; Gentile M; Salutari V; Ricci C; Musacchio L; Carbone MV; Ghizzoni V; Camarda F; Tronconi F; Nero C; Ciccarone F; Scambia G; Lorusso D
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    Miller RE; El-Shakankery KH; Lee JY
    J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance.
    Kyo S; Kanno K; Takakura M; Yamashita H; Ishikawa M; Ishibashi T; Sato S; Nakayama K
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer.
    Dong R; Ding T; Li Z
    Front Pharmacol; 2023; 14():1164395. PubMed ID: 37426808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities.
    Zielli T; Labidi-Galy I; Del Grande M; Sessa C; Colombo I
    Cancer Drug Resist; 2023; 6(3):499-516. PubMed ID: 37842243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
    Washington CR; Moore KN
    Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    Vanacker H; Romeo C; Ray-Coquard I
    Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for the prevention or reversal of PARP inhibitor resistance.
    Mitri Z; Goodyear SM; Mills G
    Expert Rev Anticancer Ther; 2024 Aug; ():1-17. PubMed ID: 39145413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of PARP inhibitor resistance and potential overcoming strategies.
    Fu X; Li P; Zhou Q; He R; Wang G; Zhu S; Bagheri A; Kupfer G; Pei H; Li J
    Genes Dis; 2024 Jan; 11(1):306-320. PubMed ID: 37588193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    Pham MM; Hinchcliff E; Avila M; Westin SN
    Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
    Hinchcliff E; Chelariu-Raicu A; Westin SN
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):19-25. PubMed ID: 33315700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches.
    Dilmac S; Ozpolat B
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors in non-ovarian gynecologic cancers.
    Fernandes I; Chehade R; MacKay H
    Ther Adv Med Oncol; 2024; 16():17588359241255174. PubMed ID: 38882441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.